E Edwards Lifesciences
| Market Cap | $47.07B |
| P/E Ratio | 44.78 |
| Forward P/E | 24.48 |
| Dividend Yield | — |
| Beta | 0.94 |
| 52W Range | $67.07 - $87.18 |
| # Hedge Funds | 3 |
| Sector | Healthcare |
| Industry | Medical Devices |
Hedge Fund Ownership
| Investor 4 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| David Rolfe Wedgewood Partners | 2.88% | $15.42M | 180,882 | Reduce 2.07% |
| Torray Funds Torray Investment Partners | 0.04% | $255.00K | 2,994 | — |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.01% | $288.00K | 3,389 | Reduce 5.02% |
| Viking Global Investors Viking Global Investors | 0.00% | $0 | 0 | Sold |
Insider Trading
| Insider Name of the company insider who made the trade 27 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 18,004 | $80.05 | $1.44M | 02 Apr 2026 | 02 Apr 2026 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 4,676 | $80.59 | $376.85K | 02 Apr 2026 | 02 Apr 2026 |
| Lippis Daniel J.CVP, TAVR | Sale | 1,019 | $85.38 | $87.00K | 11 Mar 2026 | 11 Mar 2026 |
| Ullem Scott B.CVP, Chief Financial Officer | Sale | 7,901 | $85.21 | $673.23K | 11 Mar 2026 | 11 Mar 2026 |
| Ullem Scott B.CVP, Chief Financial Officer | Sale | 5,099 | $84.46 | $430.67K | 11 Mar 2026 | 11 Mar 2026 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 11,340 | $85.93 | $974.43K | 02 Mar 2026 | 02 Mar 2026 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 24,000 | $83.84 | $2.01M | 25 Feb 2026 | 26 Feb 2026 |
| Zovighian Bernard JCEO | Sale | 2,532 | $77.13 | $195.29K | 12 Feb 2026 | 13 Feb 2026 |
| Zovighian Bernard JCEO | Sale | 19,898 | $76.61 | $1.52M | 12 Feb 2026 | 13 Feb 2026 |
| Lippis Daniel J.CVP, TAVR | Sale | 1,019 | $85.70 | $87.33K | 09 Jan 2026 | 09 Jan 2026 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 8,708 | $85.98 | $748.71K | 06 Jan 2026 | 06 Jan 2026 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 2,632 | $84.62 | $222.72K | 06 Jan 2026 | 06 Jan 2026 |
| Donald E Bobo JRCVP,Strategy/Corp Development | Sale | 2,632 | $84.62 | $222.72K | 06 Jan 2026 | 06 Jan 2026 |
| Donald E Bobo JRCVP,Strategy/Corp Development | Sale | 8,708 | $85.98 | $748.71K | 06 Jan 2026 | 06 Jan 2026 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 5,900 | $83.74 | $494.07K | 12 Dec 2025 | 12 Dec 2025 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 5,486 | $83.79 | $459.67K | 12 Dec 2025 | 12 Dec 2025 |
| STONE HEISZ LESLIE | Sale | 2,615 | $83.41 | $218.12K | 12 Dec 2025 | 12 Dec 2025 |
| Lippis Daniel J.CVP, JAPAC | Sale | 1,019 | $84.03 | $85.63K | 12 Dec 2025 | 12 Dec 2025 |
| Chopra DaveenCVP, TMTT & Surgical | Sale | 2,000 | $84.38 | $168.75K | 11 Dec 2025 | 11 Dec 2025 |
| Zovighian Bernard JCEO | Sale | 3,863 | $83.45 | $322.37K | 10 Dec 2025 | 10 Dec 2025 |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | 11,340 | $83.83 | $950.58K | 10 Dec 2025 | 10 Dec 2025 |
| Ullem Scott B.CVP, Chief Financial Officer | Sale | 7,700 | $84.47 | $650.41K | 09 Dec 2025 | 09 Dec 2025 |
| Zovighian Bernard JCEO | Sale | 21,487 | $85.21 | $1.83M | 08 Dec 2025 | 10 Dec 2025 |
| Markowitz WayneCVP, JAPAC | Sale | 583 | $86.01 | $50.14K | 08 Dec 2025 | 08 Dec 2025 |
| Ullem Scott B.CVP, Chief Financial Officer | Sale | 10,026 | $83.02 | $832.36K | 10 Nov 2025 | 10 Nov 2025 |
| Lippis Daniel J.CVP, JAPAC | Sale | 1,020 | $82.55 | $84.20K | 10 Nov 2025 | 10 Nov 2025 |
| Ullem Scott B.CVP, Chief Financial Officer | Sale | 2,974 | $83.30 | $247.73K | 10 Nov 2025 | 10 Nov 2025 |
Frequently Asked Questions
What is EW stock price today?
Edwards Lifesciences (EW) is currently trading at $81.05. The stock has a 52-week range of $67.07 to $87.18 and a market capitalization of $47.07B.
Is EW a good stock to buy in 2026?
Edwards Lifesciences has a P/E ratio of 44.8 (forward P/E: 24.5), a dividend yield of none, and 1-year performance of +11.1%. 4 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling EW stock?
There have been 27 insider transactions for EW in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has EW stock performed over the past year?
Edwards Lifesciences (EW) has returned +11.1% over the past 12 months. The stock traded between $67.07 and $87.18 during this period, and is currently at $81.05.
Which hedge funds own EW (Edwards Lifesciences)?
4 tracked hedge funds currently hold EW in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is EW's market cap and valuation?
Edwards Lifesciences (EW) has a market capitalization of $47.07B. The trailing P/E ratio is 44.8 and forward P/E is 24.5. The stock is classified in the Healthcare sector.
What is EW's revenue and profitability?
Edwards Lifesciences reported revenue of $6.07B with net income of $1.06B and a profit margin of 0.18%. The stock has a beta of 0.94.
What sector is EW in and who are its biggest institutional holders?
Edwards Lifesciences (EW) operates in the Healthcare sector. It is held by 4 tracked hedge funds. See the ownership table above for the complete list.